Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers

American Journal of Surgical Pathology

Volumn 33, Issue 7, 2009, Pages 1093-1097

  Collins, Laura C ^a   Martyniak, Anthony ^b   Kandel, Michaela J ^d   Stadler, Zsofia K ^e   Masciari, Serena ^c   Miron, Alexander ^c   Richardson, Andrea L ^b   Schnitt, Stuart J ^a   Garber, Judy E ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DR HORST SCHMIDT KLINIKEN   (Germany)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Basal cytokeratins; Basal, BRCA1 mutation; Breast cancer

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; P CADHERIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADENOID CYSTIC CARCINOMA; ARTICLE; BREAST CANCER; CANCER GRADING; FEMALE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INVASIVE CARCINOMA; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; METAPLASIA; ONCOGENE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

BREAST NEOPLASMS; FEMALE; GENES, BRCA1; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649540912     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31819c1c93     Document Type: Article

References (17)

1. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005;116:340-350.
2. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203:661-671.
3. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res. 2005;11:4003-4011.
4. Armes JE, Egan AJ, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a populationbased study. Cancer. 1998;83:2335-2345.
5. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-7360.
6. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin Cancer Res. 2008;14:1368-1376.
7. Eerola H, Heinonen M, Heikkila P, et al. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res. 2008;10:R17.
8. Farshid G, Balleine RL, Cummings M, et al. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol. 2006;30:1357-1366.
9. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485.
10. Korkko J, Annunen S, Pihlajamaa T, et al. Conformation sensitive gel electrophoresis for simple and accurate detection of mutations: comparison with denaturing gradient gel electrophoresis and nucleotide sequencing. Proc Natl Acad Sci USA. 1998;95:1681-1685.
11. Laakso M, Loman N, Borg A, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005;18:1321-1328.
12. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res. 2005;11:5175-5180.
13. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20:2310-2318.
14. Lynch BJ, Holden JA, Buys SS, et al. Pathobiologic characteristics of hereditary breast cancer. Hum Pathol. 1998;29:1140-1144.
15. Matros E, Wang ZC, Lodeiro G, et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat. 2005;91:179-186.
16. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
17. Tai YC, Chen S, Parmigiani G, et al. Incorporating tumor immunohistochemical markers in BRCA1 and BRCA2 carrier prediction. Breast Cancer Res. 2008;10:401.